Oncotalks hematology videos and news

ASH

Interviews recorded at the American Society of Hematology congress

​​Fermín Sánchez-Guijo, MD, PhD​; ENESTPath Leukemic Stem Cell (LSC) Sub-study: Analyzing Characteristics of LSC-positive Patients and Impact of Switch From Imatinib to Nilotinib Therapy on Leukemic Stem Cells in Patients With CML

​​Fermín Sánchez-Guijo, MD, PhD​; ENESTPath Leukemic Stem Cell (LSC) Sub-study: Analyzing Characteristics of LSC-positive Patients and Impact of Switch From Imatinib to Nilotinib Therapy on Leukemic Stem Cells in Patients With CML

Fermín Sánchez-Guijo, MD, PhD from the University of Salamanca, Spain is commenting on the abstract: ENESTPath Leukemic Stem Cell (LSC) Sub-study: Analyzing Characteristics of LSC-positive Patients and Impact of Switch From Imatinib to Nilotinib Therapy on Leukemic Stem Cells in Patients With Chronic Myeloid Leukemia (CPO)Blood (2019) 134 (Supplement_1): 4160https://doi.org/10.1182/blood-2019-124710
ASH , Lithuania
00:04:32
Francois-Xavier Mahon, MD, PhD; The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients.

Francois-Xavier Mahon, MD, PhD; The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients.

Francois-Xavier Mahon, MD, PhD from the University of Bordeaux, Bordeaux, France is commenting on: The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.Blood (2019) 134 (Supplement_1): 494.https://doi.org/10.1182/blood-2019-123674
ASH , Lithuania
00:03:56
Francesco Buccisano, MD; Leukemic Stem Cells Persistence Measured By Multiparametric Flow Cytometry Is a Biomarker of Poor Prognosis in Adult Patients with Acute Myeloid Leukemia

Francesco Buccisano, MD; Leukemic Stem Cells Persistence Measured By Multiparametric Flow Cytometry Is a Biomarker of Poor Prognosis in Adult Patients with Acute Myeloid Leukemia

Francesco Buccisano, MD from the University of Rome Tor Vergata, Rome, Italy is commenting on the abstract: Leukemic Stem Cells Persistence Measured By Multiparametric Flow Cytometry Is a Biomarker of Poor Prognosis in Adult Patients with Acute Myeloid LeukemiaBlood (2019) 134 (Supplement_1): 2688.https://doi.org/10.1182/blood-2019-128025
ASH , Lithuania , Albania
00:02:32
Guillaume Moulis, MD, PhD; Elextra Study & Risk of Cataract in Immune Thrombocytopenia Adult Patients Treated with Eltrombopag. a French Nationwide Nested Case-Control Study

Guillaume Moulis, MD, PhD; Elextra Study & Risk of Cataract in Immune Thrombocytopenia Adult Patients Treated with Eltrombopag. a French Nationwide Nested Case-Control Study

Guillaume Moulis, MD, PhD from the University of Toulouse, Toulouse, France is commenting on the abstract: Elextra Study & Risk of Cataract in Immune Thrombocytopenia Adult Patients Treated with Eltrombopag. a French Nationwide Nested Case-Control StudyBlood (2019) 134 (Supplement_1): 2363.https://doi.org/10.1182/blood-2019-124729
ASH , Lithuania , Albania
00:05:31
Prof. Heinz Gisslinger, MD; Ruxolitinib (RUX) Induced Meaningful and Directional Changes in the Bone Marrow Microenvironment of Patients with Myelofibrosis Enrolled in the COMFORT-I Study

Prof. Heinz Gisslinger, MD; Ruxolitinib (RUX) Induced Meaningful and Directional Changes in the Bone Marrow Microenvironment of Patients with Myelofibrosis Enrolled in the COMFORT-I Study

Prof. Heinz Gisslinger, MD from the Medical University of Vienna, Austria is commenting on the abstract: Ruxolitinib (RUX) Induced Meaningful and Directional Changes in the Bone Marrow Microenvironment of Patients with Myelofibrosis Enrolled in the COMFORT-I StudyBlood (2019) 134 (Supplement_1): 2948.https://doi.org/10.1182/blood-2019-124343
ASH , Lithuania
00:04:01
Jean-Jacques Kiladjian, MD, PhD; Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study

Jean-Jacques Kiladjian, MD, PhD; Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study

Jean-Jacques Kiladjian, MD, PhD from the Hopital Saint-Louis, Paris, France is commenting on the abstract: Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled StudyBlood (2019) 134 (Supplement_1): 553.https://doi.org/10.1182/blood-2019-122233
ASH , Lithuania , Albania
00:03:44
Jordi Esteve, MD, PhD; Final Results of the AML12 Trial of the Spanish Cetlam Group in Adults with Acute Myeloid Leukemia (AML) up to the Age of 70 Years

Jordi Esteve, MD, PhD; Final Results of the AML12 Trial of the Spanish Cetlam Group in Adults with Acute Myeloid Leukemia (AML) up to the Age of 70 Years

Jordi Esteve, MD, PhD from the Hospital Clínic of Barcelona, Barcelona, Spain is commenting on the abstract: Final Results of the AML12 Trial of the Spanish Cetlam Group in Adults with Acute Myeloid Leukemia (AML) up to the Age of 70 Years: Risk Adapted Post-Remission Allocation Based on Genetic Data and Minimal Residual DiseaseBlood (2019) 134 (Supplement_1): 289.https://doi.org/10.1182/blood-2019-128682
ASH , Lithuania , Albania
00:02:21
Mariane de Montalembert, MD, PhD; Crizanlizumab Versus Placebo, (STAND)

Mariane de Montalembert, MD, PhD; Crizanlizumab Versus Placebo, (STAND)

Mariane de Montalembert, MD, PhD from the Hôpital Necker-Enfants malades, Paris, France is commenting on the abstract: Crizanlizumab Versus Placebo, with or without Hydroxyurea/Hydroxycarbamide, in Adolescent and Adult Patients with Sickle Cell Disease and Vaso-Occlusive Crises: A Randomized, Double-Blind, Phase III Study (STAND)Blood (2019) 134 (Supplement_1): 998.https://doi.org/10.1182/blood-2019-125775
ASH , Lithuania , Albania
00:04:57

This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies . If you require further information and/or do not wish to have cookies placed when using the site, visit Privacy Notice.

On acceptance: use all cookie settings
On denial: use only necessary cookies